Patents by Inventor Emmanuel Favry

Emmanuel Favry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic peptides of the cyclin B1 tumor antigen
    Patent number: 10550166
    Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: February 4, 2020
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Bernard Maillere, Claire Chevaleyre, Florence Castelli-Golfier, Emmanuel Favry, Anaïs M'Houmadi
  • Immunogenic Peptides of the Cyclin B1 Tumor Antigen
    Publication number: 20180086804
    Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.
    Type: Application
    Filed: September 12, 2017
    Publication date: March 29, 2018
    Inventors: Bernard Maillere, Claire Chevaleyre, Florence Castelli-Golfier, Emmanuel Favry, Anaïs M'Houmadi
  • IMMUNOGENIC PEPTIDES OF THE CYCLIN B1 TUMOR ANTIGEN
    Publication number: 20160257727
    Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.
    Type: Application
    Filed: July 4, 2014
    Publication date: September 8, 2016
    Applicant: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Bernard Maillere, Claire Chevaleyre, Florence Castelli-Golfier, Emmanuel Favry, Anaïs Mouhmadi
  • Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine
    Publication number: 20110159022
    Abstract: A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.
    Type: Application
    Filed: June 20, 2009
    Publication date: June 30, 2011
    Inventors: Jérôme Kerzerho, Bernard Maillere, Emmanuel Favry